These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20166888)

  • 1. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
    Kernt M; Liegl RG; Rueping J; Neubauer AS; Haritoglou C; Lackerbauer CA; Eibl KH; Ulbig MW; Kampik A
    Growth Factors; 2010 Jun; 28(3):211-20. PubMed ID: 20166888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF.
    Kernt M; Neubauer AS; Liegl RG; Hirneiss C; Alge CS; Wolf A; Ulbig MW; Kampik A
    Br J Ophthalmol; 2010 Nov; 94(11):1533-9. PubMed ID: 20962354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium].
    Kernt M; Thiele S; Hirneiss C; Neubauer AS; Lackerbauer CA; Wolf A; Eibl KH; Haritoglou C; Ulbig MW; Kampik A
    Ophthalmologe; 2011 May; 108(5):445-51. PubMed ID: 21253747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiogenic growth factor combinations on retinal endothelial cells.
    Castellon R; Hamdi HK; Sacerio I; Aoki AM; Kenney MC; Ljubimov AV
    Exp Eye Res; 2002 Apr; 74(4):523-35. PubMed ID: 12076096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
    Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
    Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia.
    Simpson DA; Murphy GM; Bhaduri T; Gardiner TA; Archer DB; Stitt AW
    Biochem Biophys Res Commun; 1999 Aug; 262(2):333-40. PubMed ID: 10462475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
    Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2012 Apr; 32(4):574-81. PubMed ID: 22176637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
    J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
    Mejias M; Garcia-Pras E; Tiani C; Miquel R; Bosch J; Fernandez M
    Hepatology; 2009 Apr; 49(4):1245-56. PubMed ID: 19137587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
    J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sorafenib in postoperative adhesion formation in a rat uterine horn model.
    Boztosun A; Ozer H; Altun A; Kiliçkap S; Gulturk S; Müderris II; Yanik A
    Clin Exp Obstet Gynecol; 2012; 39(3):351-5. PubMed ID: 23157042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
    Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
    Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
    Reiberger T; Angermayr B; Schwabl P; Rohr-Udilova N; Mitterhauser M; Gangl A; Peck-Radosavljevic M
    J Hepatol; 2009 Nov; 51(5):865-73. PubMed ID: 19726100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy.
    Yamada H; Yamada E; Ando A; Seo MS; Esumi N; Okamoto N; Vinores M; LaRochelle W; Zack DJ; Campochiaro PA
    Am J Pathol; 2000 Feb; 156(2):477-87. PubMed ID: 10666377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
    Pinter M; Sieghart W; Reiberger T; Rohr-Udilova N; Ferlitsch A; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2012 Jan; 35(1):83-91. PubMed ID: 22032637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
    Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.